Intracardiac thrombosis during liver transplant: A 17-year single-institution study.
Intracardiac thrombosis (ICT) during orthotopic liver transplantation (OLT) is an uncommon event. However, it is a devastating complication with high mortality when it occurs. This study aimed to identify possible predisposing factors for ICT during OLT. We retrospectively identified the cases of all patients with ICT during OLT at our institution from 1998 to 2014. Of 2750 OLTs performed, 10 patients had ICT intraoperatively. The patients' immediate prethrombosis intraoperative hemodynamic and coagulation values and thromboelastography (TEG) data were reviewed. Preexisting venous thrombosis, atrial fibrillation, and the prior placement of a transjugular intrahepatic portosystemic shunt for portal hypertension were noted in several patients and may be related to ICT during OLT. A high Model of End-Stage Liver Disease score, low cardiac output, and sepsis did not appear to be associated with ICT. ICT occurred in some patients without the administration of antifibrinolytic agents. TEG and coagulation parameters did not appear to be helpful in predicting the onset of ICT. Four patients had ICT in both right- and left-sided heart chambers; none of these 4 patients survived. All 6 patients with only right-sided thrombus survived. In those who survived, improved hemodynamics and clot disappearance on transesophageal echocardiography (TEE) occurred over time, even without the use of thrombolytics. Whether this is because of endogenous thrombolysis or distal clot propagation into the pulmonary vasculature, or both, is unclear. Tissue plasminogen activator may have a role in the resuscitation procedure. In conclusion, without the routine use of TEE during OLT, the incidence of ICT will remain an under-recognized event.
Department of Anesthesiology, Mayo Clinic, Jacksonville, FL.
Prith
P
Peiris
Department of Anesthesiology, Mayo Clinic, Jacksonville, FL.
Sher-Lu
SL
Pai
Department of Anesthesiology, Mayo Clinic, Jacksonville, FL.
Stephen
S
Aniskevich
Department of Anesthesiology, Mayo Clinic, Jacksonville, FL.
Claudia C
CC
Crawford
Department of Anesthesiology, Mayo Clinic, Jacksonville, FL.
Klaus D
KD
Torp
Department of Anesthesiology, Mayo Clinic, Jacksonville, FL.
Beth L
BL
Ladlie
Department of Anesthesiology, Mayo Clinic, Jacksonville, FL.
Timothy S
TS
Shine
Division of Transplant Surgery, Mayo Clinic, Jacksonville, FL.
C Burcin
CB
Taner
Division of Transplant Surgery, Mayo Clinic, Jacksonville, FL.
Justin H
JH
Nguyen
D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001777:Blood Coagulation; D016208:Databases, Factual; D017548:Echocardiography, Transesophageal; D005260:Female; D005431:Florida; D006331:Heart Diseases / Q000097:blood / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D016019:Survival Analysis; D013916:Thrombelastography; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000097:blood / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome
D000933:Antifibrinolytic Agents